Genomic Test Helps Estimate Risk of Prostate Cancer Metastasis ...

The investigators found that the Decipher test, which measures the activity of 22 genes among seven known cancer pathways, independently ...

Test May Show Whether to Treat Prostate Cancer with Hormones - NCI

Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide ... By estimating the future risk of prostate cancer spread and death, the ...

Can a Genomic Test Better Detect Aggressive Prostate Cancer? - NCI

The genomic test, called Decipher, looks at the activity of 22 genes and has been shown to predict the risk that a prostate tumor will spread ( ...

Can We Predict Prostate Cancer Metastasis Based on Biomarkers ...

Oncotype DX is a biopsy-based genomic test designed as a reverse transcription polymerase chain reaction assay that has been analytically validated to measure ...

Genetic and Genomic Testing for Prostate Cancer: Beyond DNA ...

Polygenic risk scores are poised to improve risk evaluation in future. ... RNA expression tests (using prostate tissue) can help inform treatment ...

Toward Informed Selection and Interpretation of Clinical Genomic ...

In prostate cancer (PCa), broad genotyping tests are now widely used to identify germline and/or somatic alterations in BRCA2 and other DNA ...

Biomarkers & Genomic Testing - ZERO Prostate Cancer

Biomarker testing - also called comprehensive genomic profiling (CGP), tumor testing, molecular profiling, tumor subtyping, or somatic testing - uses a single ...

Genomic Test Helps Estimate Risk of Prostate Cancer Metastasis ...

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, ...

Association Between the Decipher Genomic Classifier and Prostate ...

Looking at the results of 58 935 participants who underwent testing, we found that the Decipher test helped estimate the risk of cancer ...

Guidelines for genetic testing in prostate cancer: a scoping review

Essentially, germline testing is recommended for men with high- or very high-risk prostate cancer, regional or metastatic prostate cancer, ...

Genomic test helps estimate risk of prostate cancer metastasis, death

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from ...

Actionable Insights for Physicians | Veracyte - Decipher Prostate

Our tissue-based test has been validated in more than 80 studies and 200,000 patients as a highly accurate predictor of metastasis, prostate cancer-specific ...

Patient experiences with tissue‐based genomic testing during active ...

Background Tissue-based gene expression (genomic) tests provide estimates of prostate cancer aggressiveness and are increasingly used for ...

Genetic Counseling and Testing for Prostate Cancer Risk

The main benefit of genetic testing is that it can help you better understand your risk for a certain disease, such as prostate cancer. Genetic ...

Men With Metastatic Prostate Cancer Need Genetic Testing

This suggests that genetic tests for defects in DNA-damage repair genes can identify individuals and families with a predisposition to prostate cancer, as well ...

Genetic Testing | ZERO Prostate Cancer

A genetic test can help you know the likelihood of family members developing prostate or breast cancer. It can also impact treatment decisions for prostate ...

Genetic Testing for Prostate Cancer

This is referred to as genetic testing for an inherited mutation or genetic testing for inherited cancer risk. (You may also hear it called “germline genetic ...

Prolaris Test for Prostate Cancer Risk Assessment - AAFP

Prolaris is a genomic test that analyzes changes in 46 genes in prostate biopsy tissue. It generates a risk score to help predict the likelihood of disease ...

Risk Groups and Lab Tests to Help Determine Risk from Localized ...

(Higher scores indicate a cancer that is more likely to grow and spread quickly, as well as a higher risk of dying from prostate cancer.) ...

Active surveillance selection and 3-year durability in intermediate ...

Genomic testing can add risk stratification information to clinicopathological features in prostate cancer, aiding in shared medical ...